Corcept Therapeutics Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Corcept Therapeutics verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 0.4%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 9.4%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 18.7%. Die Eigenkapitalrendite von Corcept Therapeutics beträgt 7.4% und die Nettomargen betragen 6.1%.
Wichtige Informationen
0.39%
Wachstumsrate der Gewinne
2.93%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.95% |
| Wachstumsrate der Einnahmen | 18.71% |
| Eigenkapitalrendite | 7.42% |
| Netto-Marge | 6.07% |
| Letzte Ertragsaktualisierung | 31 Mar 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
CORT: Ovarian Cancer Data And Cushing’s Resubmission Will Drive Future Upside
Corcept Therapeutics' updated analyst price target has increased to $88.00 from $73.40, reflecting analysts' focus on recent price target revisions associated with the relacorilant NDA resubmission and the launch of Lifyorli in ovarian cancer. Analyst Commentary Recent Street research around Corcept Therapeutics centers on two main themes, the relacorilant regulatory path and the commercial opportunity for Lifyorli in ovarian cancer, with both feeding directly into updated valuation work.CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking AlphaCORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...Aufschlüsselung der Einnahmen und Ausgaben
Wie Corcept Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Mar 26 | 769 | 47 | 503 | 260 |
| 31 Dec 25 | 761 | 98 | 449 | 255 |
| 30 Sep 25 | 741 | 105 | 402 | 260 |
| 30 Jun 25 | 716 | 132 | 352 | 251 |
| 31 Mar 25 | 685 | 133 | 315 | 249 |
| 31 Dec 24 | 675 | 140 | 280 | 247 |
| 30 Sep 24 | 629 | 140 | 244 | 231 |
| 30 Jun 24 | 570 | 125 | 216 | 217 |
| 31 Mar 24 | 524 | 117 | 192 | 202 |
| 31 Dec 23 | 482 | 105 | 184 | 184 |
| 30 Sep 23 | 450 | 91 | 179 | 166 |
| 30 Jun 23 | 428 | 94 | 169 | 154 |
| 31 Mar 23 | 414 | 94 | 164 | 144 |
| 31 Dec 22 | 402 | 101 | 153 | 131 |
| 30 Sep 22 | 398 | 117 | 143 | 123 |
| 30 Jun 22 | 392 | 113 | 138 | 118 |
| 31 Mar 22 | 380 | 112 | 130 | 113 |
| 31 Dec 21 | 366 | 113 | 122 | 114 |
| 30 Sep 21 | 353 | 106 | 116 | 114 |
| 30 Jun 21 | 343 | 98 | 112 | 119 |
| 31 Mar 21 | 340 | 99 | 107 | 118 |
| 31 Dec 20 | 354 | 106 | 105 | 115 |
| 30 Sep 20 | 356 | 109 | 107 | 111 |
| 30 Jun 20 | 351 | 114 | 104 | 100 |
| 31 Mar 20 | 335 | 106 | 104 | 95 |
| 31 Dec 19 | 306 | 94 | 100 | 89 |
| 30 Sep 19 | 285 | 87 | 95 | 83 |
| 30 Jun 19 | 268 | 78 | 92 | 80 |
| 31 Mar 19 | 258 | 76 | 87 | 78 |
| 31 Dec 18 | 251 | 75 | 81 | 75 |
| 30 Sep 18 | 238 | 152 | 77 | 70 |
| 30 Jun 18 | 216 | 148 | 72 | 63 |
| 31 Mar 18 | 189 | 142 | 66 | 50 |
| 31 Dec 17 | 159 | 129 | 62 | 40 |
| 30 Sep 17 | 130 | 35 | 57 | 33 |
| 30 Jun 17 | 109 | 24 | 52 | 29 |
| 31 Mar 17 | 93 | 13 | 50 | 26 |
| 31 Dec 16 | 81 | 8 | 45 | 24 |
| 30 Sep 16 | 72 | 5 | 42 | 21 |
| 30 Jun 16 | 64 | 1 | 41 | 18 |
| 31 Mar 16 | 56 | -2 | 38 | 16 |
| 31 Dec 15 | 50 | -6 | 37 | 15 |
| 30 Sep 15 | 44 | -11 | 36 | 15 |
| 30 Jun 15 | 38 | -17 | 36 | 15 |
Qualität der Erträge: CORT hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: CORTDie aktuellen Gewinnspannen (6.1%) sind niedriger als im letzten Jahr (19.3%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: CORTIn den letzten 5 Jahren sind die Gewinne von 0.4% jährlich gestiegen.
Beschleunigtes Wachstum: CORTDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: CORT hatte im vergangenen Jahr ein negatives Gewinnwachstum (-64.8%), was einen Vergleich mit dem Branchendurchschnitt Pharmaceuticals (-4.8%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: CORTDie Eigenkapitalrendite des Unternehmens (7.4%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/08 15:28 |
| Aktienkurs zum Tagesende | 2026/06/08 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Corcept Therapeutics Incorporated wird von 18 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |